Catalent's Eberbach, Germany Site Celebrates 60 Years Helping Rx And OTC Customers Succeed With Softgel Technologies




Catalent's Eberbach, Germany Site Celebrates 60 Years Helping Rx and OTC Customers Succeed with Softgel Technologies

Date: 10/13/2010

SOMERSET NJ, October 13, 2010 — Catalent’s R.P. Scherer softgel business based in Eberbach, Germany is celebrating 60 years of service to the health care industry. R.P. Scherer Eberbach’s longevity and success have been fueled by its unique combination of innovative formulation technology and strong commitment to customer service that ensures optimum speed-to-market and return on investment for its customers.

R.P. Scherer Eberbach has a rich history that began in post-war Germany. When Heinrich Koepff, a German gelatin producer, who later went on to form the company now known as Gelita AG, contacted Robert P. Scherer, inventor of the rotary die production of softgel capsules and head of R.P. Scherer Corporation in the United States, the wheels were set in motion for the formation of R.P. Scherer Germany, the first American-German joint venture after World War II. Today, R.P. Scherer Eberbach is an integral part of Catalent Pharma Solutions and is celebrating its 60th anniversary as a leading producer of softgel capsules. R. P. Scherer Eberbach has developed into a fully integrated service provider for the health care industry, offering a broad range of encapsulation products and services including formulation development of new products, development and validation of analytical methods, registration support and full-scale manufacturing.

Over the years, the R.P. Scherer Eberbach facility has seen a number of milestones. In late 1950, the first rotary die machines were installed in Eberbach, and the first softgel capsules rolled out to the market. In 1963, an additional production building was opened. A second expansion that began in 1987 included another new production facility and a high-bay warehouse. In 1996, the Eberbach facility was upgraded to a modern pharmaceutical softgel production site. In 2003 a major milestone was achieved with the successful completion of the ‘Eberbach 2000’ project to ensure that the facility would remain a state of the art pharmaceutical operation for years to come.

Today, the R.P Scherer Eberbach facility and its more than 700 employees deliver products and services to nearly 250 customers; and produce approximately 13.5 billion standard capsules for Catalent’s global customers, making it one of the highest volume softgel capsule manufacturing sites in the world.

“I would like to offer congratulations to the entire Eberbach team on 60 years of contributions to our business and to the health and wellness of people all over the world,” said Stefan Juetten, General Manager of R.P. Scherer Eberbach. “While the first 60 years proved to be very successful, R.P. Scherer Eberbach is already preparing for the future to meet our commitments to provide outstanding customer service while focusing on the imperative of continuous improvement.”
 
 Currently underway is the installation of a new $8 million manufacturing and enterprise resource information system to be completed later in 2010. Another significant investment has just begun with the expansion of the site’s lab analytical services to meet growing customer demand.

To learn more about the softgel technologies manufactured at Catalent’s R.P. Scherer Eberbach facility and worldwide, go to: http://www.catalent.com/offerings/manufacturing/oral-dose-forms/softgel-capsules .

For specific softgel manufacturing inquiries or to arrange a site tour of Catalent’s R.P. Scherer Eberbach facility, please contact Dr. Uwe Schmelzer at Uwe.Schmelzer@catalent.com .

About Catalent

Headquartered in Somerset, New Jersey, Catalent is a leading provider of advanced dose form and packaging technologies, and development, manufacturing, packaging and printing services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,000 at 29 facilities worldwide and in fiscal 2010 generated more than $1.7 billion of annual revenue. For more information, visit www.catalent.com.

more products. better treatments. reliably supplied.™